KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xenon Pharmaceuticals (XENE) Change in Receivables (2016 - 2025)

Xenon Pharmaceuticals (XENE) has disclosed Change in Receivables for 13 consecutive years, with $559000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Change in Receivables rose 2.19% to $559000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was -$104000.0, a 116.94% decrease, with the full-year FY2025 number at -$104000.0, down 116.94% from a year prior.
  • Change in Receivables was $559000.0 for Q4 2025 at Xenon Pharmaceuticals, up from -$283000.0 in the prior quarter.
  • In the past five years, Change in Receivables ranged from a high of $7.2 million in Q1 2025 to a low of -$7.6 million in Q2 2025.
  • A 5-year average of -$45900.0 and a median of -$22500.0 in 2022 define the central range for Change in Receivables.
  • Biggest YoY gain for Change in Receivables was 18989.47% in 2025; the steepest drop was 34454.55% in 2025.
  • Xenon Pharmaceuticals' Change in Receivables stood at -$481000.0 in 2021, then plummeted by 214.97% to -$1.5 million in 2022, then soared by 119.41% to $294000.0 in 2023, then surged by 86.05% to $547000.0 in 2024, then grew by 2.19% to $559000.0 in 2025.
  • Per Business Quant, the three most recent readings for XENE's Change in Receivables are $559000.0 (Q4 2025), -$283000.0 (Q3 2025), and -$7.6 million (Q2 2025).